BMS’s Deucravacitinib Superior to Otezla (apremilast) and Placebo in POETYK PSO-2 Psoriasis Trial
Bristol-Myers Squibb announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib for the treatment of […]
Verrica Pharmaceuticals Presents Positive Results for Molluscum, Genital Warts Treatment
Verrica Pharmaceuticals presented data two clinical trials evaluating the safety and efficacy of VP-102, a proprietary drug-device combination product in […]
Oncosec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma
Oncosec Medical announced positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVO (tavokinogene telseplasmid) in combination […]
Arena Pharma’s Etrasimod Effective in Treating Atopic Dermatitis in Phase 2b Trial
Arena Pharmaceuticals announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod for the treatment of moderate-to-severe atopic […]
Bristol Myers Squibb’s Deucravacitinib Superior to Amgen’s Otezla (apremilast) and Placebo in Pivotal Phase 3 Psoriasis Study
Bristol-Myers Squibb reported positive results from POETYK PSO-1, the first pivotal Phase 3 trial evaluating deucravacitinib (BMS-986165) versus Otezla (apremilast) […]
Biogen Reports Data for Systemic Lupus Erythematosus Portion of Phase 2 LILAC Study Showing Efficacy of BIIB059 in Reducing Joint Disease Activity
Biogen announced positive data from the 24-week systemic lupus erythematosus (SLE) portion of the Phase 2 LILAC study (part A) […]
ChemoCentryx Announces Positive Topline Results from Phase 2 AURORA Trial of Avacopan for Hidradenitis Suppurativa
ChemoCentryx reported positive topline results from the phase 2 AURORA trial which evaluated the efficacy of avacopan versus placebo in […]
Data from Soligenix Phase 3 FLASH Study Shows Continued Long-Term Benefit of SGX301 in Treating Cutaneous T-Cell Lymphoma
Soligenix announced results from the compassionate use, optional cycle (cycle 3) of the phase 3 FLASH trial, which evaluated SGX301 […]
LEO Pharma Announces Data from ECZTRA 1, 2 and ECZTRA 3 Phase 3 trials Published in British Journal of Dermatology
LEO Pharma announced that the British Journal of Dermatology has published primary data from the pivotal ECZTRA 1, 2 and ECZTRA 3 […]
Corbus’ Lenabasum Fails to Meet Endpoints in Phase 3 Systemic Sclerosis Trial
Corbus Pharmaceuticals announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic […]
